Form 4: AEON Biopharma Director Eric G. Carter Reports Stock Option Grants

Director Eric G. Carter reports the acquisition of stock options in AEON Biopharma, Inc.

Summary

• On March 21, 2024, Eric G. Carter, a director of AEON Biopharma, Inc., filed a Form 4 with the SEC.
• The report details the grant of two stock option awards on March 19, 2024.
• One grant is for 16,260 shares, vesting monthly over one year.
• The other grant is for 8,130 shares, vesting annually over four years.
• Both grants have an exercise price of $14.40 and expire on March 18, 2034.
• The options will vest in full upon a Change in Control of the Company.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing stock option grants, which is neutral to slightly positive as it incentivizes management.

Positives

• The stock option grants align the director's interests with the long-term success of AEON Biopharma.
• The vesting schedules encourage continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biopharmaceutical companies.
• Vesting schedules, such as monthly or annual vesting, are typical to ensure continued service.
• The specific number of options granted and the exercise price would need to be compared to similar companies of comparable size and stage of development to assess relative generosity.

Stakeholder Impact

• Shareholders may view the stock option grants positively as they align the director's interests with the company's long-term success.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates

Keywords

Form 4, stock options, AEON Biopharma, director, Eric G. Carter, beneficial ownership, securities